Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,811.75
(
0.43%
)
US TECH 100
24,339.60
(
0.40%
)
Dow Jones
48,055.86
(
0.30%
)
Brent Oil
93.58
(
-1.32%
)
Bitcoin
72,226.75
(
1.54%
)
News Focus
News Focus
Post# of 257375
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 53202

Tuesday, 10/30/2007 1:46:58 PM

Tuesday, October 30, 2007 1:46:58 PM

Post# of 257375
HCV maintenance therapy for non-responders:

SGP will present data from such a study at AASLD next week. The doses of PegIntron and ribavirin are lower than they are for standard HCV treatment, but the company hasn’t yet said how much lower.

http://biz.yahoo.com/prnews/071030/nytu018b.html?.v=2

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today